Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 23;15:157–178. doi: 10.2147/TCRM.S147318

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Farris et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Mean percentage change in menstrual blood loss during the last 28 days of treatment.

Notes: **P≤0.01; ***P≤0.001. P-values are for difference in LS mean change from baseline vs PBO. Reprinted from Fertility and Sterility, Vol 108(1), Archer DF, Stewart EA, Jain RI, et al, Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study, Pages 152–160, Copyright (2017), with permission from Elsevier.96

Abbreviations: BID, twice daily; CEP, E₂ 1 mg continuously and cyclical oral P 200 mg; E, elagolix (doses in mg); E₂/NETA, E₂ 0.5 mg and norethisterone acetate 0.1 mg continuously; LS, least squares; PBO, placebo; QD, once daily; SE, standard error.